Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × durvalumab × Clear all

Phase

Phase 3 59 Phase 1 45 Phase 2 42 Phase 1/2 18 Phase 4 2 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

OTHER 3 NIH 2 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 23 Cisplatin 23 Gemcitabine 22 Carboplatin 21 Paclitaxel 19 Docetaxel 13 Pemetrexed 12 Drug Therapy 12 Capecitabine 11 Oxaliplatin 10 Bevacizumab 9 Nivolumab 8 Fluorouracil 8 130-nm albumin-bound paclitaxel 7 anlotinib 6 Trastuzumab 6 Temozolomide 5 atezolizumab 4 Lenalidomide 4 Ipilimumab 4 Injections 4 Folfox protocol 4 venetoclax 3 pertuzumab 3 osimertinib 3 daratumumab 3 camrelizumab 3 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3 Sorafenib 3 Sirolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06109272 2025-08-15

LIVIGNO-2

AbbVie

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡